Key Takeaways
- Revenue crosses INR 1,000 crores: IPL hit the milestone for the first time in FY26, powered by ~30% Q4 volume growth and a domestic sales surge of over 50% YoY.
- Domestic strength offsets export softness: Q4 domestic revenue reached INR 183 crores while exports dipped slightly on March 2026 geopolitical disruption; the domestic-heavy product mix cushioned the impact.
- Shalvis ramp-up is the FY27 growth engine: The new facility contributed only INR 4-5 crores in FY26 but management targets INR 70-80 crores in FY27 as a second block comes online and two more molecules are added.
- Margins defended through pricing pass-through: Raw material costs rose but management successfully passed differentials to customers on some products and expects to maintain current prices, supporting an 18-20% EBITDA margin guide for FY27.
- What to watch next quarter: Whether the second Shalvis block commissions on schedule by September-October 2026, the trajectory of the two new Hamirpur molecules, and any monsoon-driven demand disruption from the IMD's 6-8% below-normal rainfall forecast.
Revenue Drivers: Domestic Surge & Volume Growth
- Volume-led quarter: Approximately 30% volume growth in Q4 came from higher production levels, efficient execution and sustained domestic market demand.
- Domestic dominance: Q4 domestic sales increased more than 50% YoY to INR 183 crores, driven largely by strong demand for herbicides and intermediates.
- Export headwind contained: Q4 export revenue decreased slightly (INR 84 crores vs INR 89 crores) due to geopolitical issues in March 2026; management noted exports were "hardly 5% less than last quarter" because one major product is domestic-oriented.
- PEDA/Pretilachlor contribution: The herbicide introduced last year with backward integration contributed significantly to revenue and volume growth; the plant runs at 70-75% utilization due to its seasonal nature, requiring a three-month stoppage from August to October.
- Make in India substitution: Domestic production has replaced imports for PEDA/Pretilachlor almost entirely, with management noting only small residual imports from earlier purchases may remain.
D. K. Jain: "At least that has been our contribution for Make in India effort that we have been able to replace this product totally from import."
Shalvis Facility: The FY27 Growth Story
- Modest FY26 start: One technical product started at Shalvis late in the year, contributing INR 4-5 crores in FY26.
- FY27 ramp-up target: Management expects at least INR 25 crores from the existing molecule, with total Shalvis revenues reaching INR 70-80 crores including the second block.
- Second block timeline: Expected to be operational by September-October 2026, adding two more molecules that management says will contribute significantly.
- FY31 ambition: Shalvis is projected to contribute about INR 1,000 crores of the INR 3,000 crores FY31 revenue target, with the rest coming from existing plants at Dewa Road, Sandila and formulation facilities.
D. K. Jain: "We expect Shalvis revenues to be in the range of at least INR 70 crores to INR 80 crores."
Hamirpur & New Molecules
- Infrastructure progressing: Development work at Hamirpur has progressed steadily; supporting infrastructure is already established and operational blocks are moving ahead as planned.
- Two entirely new molecules: These are not produced at Sandila or Dewa Road; one product will be the first to be produced in India, targeting a herbicide market currently controlled by a multinational.
- Market share expectation: Management expects about 10% of the market size for these two molecules, primarily for export, while checking with the Central Insecticides Board for India introduction.
- Intermediate plant commissioned: Enhanced capacity of an intermediate plant for backward integration of a herbicide was commissioned using in-house indigenous R&D technology, supporting supply chain stability and reducing import dependency.
- Formulation capacity scaled: Formulation capacity scaled up to 10,000 metric tonnes during the year.
D. K. Jain: "I think even with these two new molecules, there are very few producers in India. And I think one of the products, must be, we will be the first to produce in India."
Margins & Pricing
- Raw material cost pressure: Raw material costs have increased, with China raising prices and the geopolitical situation causing daily price changes; sulphur-based products increased more than others.
- Pass-through success: Management has passed on cost differentials to customers for some products and believes current prices can be maintained in coming months.
- PEDA/Pretilachlor margins: Margins on this product are more or less the same as overall averages, slightly lower but volume-driven.
- EBITDA margin guide: 18% to 20% projected for FY27, implying confidence in sustaining the pricing pass-through and operating leverage from volume growth.
- Price increase quantification avoided: When asked for the average price increase percentage across the portfolio basket, management declined to give a specific number, citing variability across products.
D. K. Jain: "We have tried to pass on the cost differential to our customer, and we have been successful in convincing them for some of the products. And we feel that we should be able to maintain these prices in the coming months."
Partnerships & Capacity
- Japanese partner scale-up: Regular discussions are ongoing; the partner's forecast for this year and next year is almost 30% higher than last year; samples for one more molecule have been submitted, awaiting feedback.
- Sandila plant constraints: The site is full with no further space for expansion; this year will add an intermediate and one technical grade product plus balancing equipment for capacity augmentation.
- PEDA capacity outlook: Management expects to utilize full PEDA capacity in FY27 since capacity was increased and commissioned only in March; FY27 will be better than FY26.
- Supply chain resilience: Long-term arrangements with suppliers for critical raw materials are in place; local supplies come at slightly higher prices but ensure continuity; discussions with customers to manage price increases are ongoing.
- Paraquat ban gap: Management acknowledged IPL's product range has no product that can substitute paraquat, and expressed uncertainty about whether their herbicide could be used as a replacement.
Capital Allocation & Balance Sheet
- Working capital improvement: Net working capital days improved to 223 from 254 days in FY25, with a further 10-12 day improvement expected by FY27; higher inventory is needed because customers are buying on a spot basis.
- Capex plan: INR 45 crores for India Pesticides and INR 90 crores for the 100% subsidiary in FY27, funded mainly through internal accruals; a small loan may be taken in the subsidiary.
- Dividend policy defended: Payout at 5% to 15% of net profit; management defended the INR 0.75 dividend against analyst pushback for a higher payout, citing capex plans and working capital needs as priorities for fund conservation.
- Buyback suggestion ignored: An analyst suggested a buyback to give confidence to the market; management did not respond to this suggestion.
D. K. Jain: "Intrinsic, if you see ultimately, the investor value will increase by conserving funds. ₹0.50 more or ₹0.25 more dividend will not significantly make investors very happy."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% to 20% increase | FY27 |
| EBITDA margin | 18% to 20% | FY27 |
| Shalvis revenue | At least INR 70-80 crores (including second block) | FY27 |
| Second Shalvis block operational | Commissioning | September-October 2026 |
| Working capital days | Improve by 10-12 days from 223 | FY27 |
| PEDA capacity utilization | Full capacity utilization | FY27 |
| Capex | INR 45 cr (IPL) + INR 90 cr (subsidiary), funded via internal accruals | FY27 |
| FY31 revenue target | INR 3,000 crores | By March 2031 |
| Shalvis FY31 contribution | About INR 1,000 crores | By March 2031 |
| Japanese partner volumes | ~30% increase over prior year | FY27 and FY28 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹271 cr, +28.5% YoY |
| Domestic revenue | ₹183 cr, +55% YoY (vs ₹118 cr in Q4 FY25) |
| Export revenue | ₹84 cr, -5.6% YoY (vs ₹89 cr in Q4 FY25); slight decrease due to geopolitical issue in March 2026 |
| EBITDA | ₹46 cr, +31.1% YoY |
| Net profit | ₹31 cr, +40.6% YoY; PAT margin 11.3% |
| Volume growth | ~30% YoY, supported by higher production levels and sustained market demand |
| FY26 full-year revenue | ₹1,078 cr, +27.9% YoY; crossed ₹1,000 cr milestone for the first time |
| FY26 full-year EBITDA | ₹194 cr, +44.7% YoY; EBITDA margin 18% (vs 15.9% in FY25) |
| FY26 full-year PAT | ₹120 cr, +45.8% YoY |
| FY26 product mix | Technicals ₹744 cr, Formulations ₹311 cr |
| FY26 domestic/export split | Domestic ₹649 cr, Export ₹408 cr (39% of total) |
| Net working capital days | 223 days, improved from 254 days in FY25 |
| ROCE | 16.8% |
| FY27 capex budget | ₹45 cr (India Pesticides), ₹90 cr (100% subsidiary); funded mainly through internal accruals |
| FY27 revenue growth guidance | 15% to 20% increase expected |
| FY27 EBITDA margin guidance | 18% to 20% |
| Shalvis facility revenue (FY26) | ₹4-5 cr |
| Shalvis facility expected revenue (FY27) | ₹70-80 cr, including second block operational by Sep-Oct 2026 |
| Pretilachlor/PEDA combined capacity | 8,500 metric tonnes; utilization ~70-75% due to seasonal three-month plant stop |
| Formulation capacity | 10,000 metric tonnes, distribution across 18 states via 24 depots and over 340 sales personnel |
| FY31 revenue target | ₹3,000 cr (Shalvis ~₹1,000 cr, existing plants ~₹2,000 cr) |
| Credit rating | A+, due for review in September |
| Dividend per share | ₹0.75 |